Keep tabs on your favorite ETFs with a personalized weekly tracker. Create a Watchlist now →

Advertisement
Advertisement

PBPHvsXLVIETF Comparison

ETF 1
PBPH

Portfolio Building Block World Pharma and Biotech Index ETF

This fund is part of
DM Large & Mid Cap
-0.57%
VS
ETF 2
XLVI

State Street Health Care Select Sector SPDR Premium Income Fund

This fund is part of
Options Strategies
-0.03%

Portfolio Building Block World Pharma and Biotech Index ETF (PBPH) belongs to the DM Large & Mid Cap segment. State Street Health Care Select Sector SPDR Premium Income Fund (XLVI) is part of the Options Strategies segment. PBPH's top 3 sector exposures are Health Care and Consumer Staples. In contrast, XLVI's top sector exposures are Health Care  PBPH is less expensive with a Total Expense Ratio (TER) of 0.13%, versus 0.35% for XLVI. PBPH is down -2.73% year-to-date (YTD) with +$787M in YTD flows. XLVI performs worse with -4.44% YTD performance, and +$2M in YTD flows. Run a side-by-side ETF comparison of PBPH and XLVI below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.

Find out how industry players manage ETF portfolios.  Discover our library of Model portfolios

PBPH vs XLVI performance and flow charts

Performance

-2.0-1.00.01.02.03.04.0%Mar 30Apr 7Apr 14Apr 21Apr 28

Cumulative Flows

010,000,00020,000,00030,000,00040,000,000Mar 30Apr 7Apr 14Apr 21Apr 28

Get all the metrics on this page, and more, through a reliable ETF data feed

Daily, global ETF data for advanced analysis or integration into apps (API), from our partner Trackinsight.

Historic performance and flows
Data as of 04/28/2026
1M3MYTD1Y3Y5Y
Perf.
PBPH
XLVI
-1.83%+0.18%
-5.37%-4.15%
-2.73%-4.44%
n/an/a
n/an/a
n/an/a
Flows
PBPH
XLVI
+$39M+$499K
+$757M+$2M
+$787M+$2M
--
--
--
Volatility and drawdown
3M1Y3Y5Y
Volatility
PBPH
XLVI
+16.32%+12.86%
n/an/a
n/an/a
n/an/a
Max drawdown
PBPH
XLVI
-9.94%-8.21%
n/an/a
n/an/a
n/an/a
Max drawdown duration
PBPH
XLVI
70d59d
n/an/a
n/an/a
n/an/a
Trading data

Create an account to view trading data

Join for free
PBPH
XLVI
Last sale
4/30/2026 at 1:30 PM
$25.03
$24.97
Previous close
04/29/2026
$24.30
$24.45
Consolidated volume
04/29/2026
Average volume
30 days
Average discount or premium
30 days
Average Bid/Ask spread
30 days
Replication quality
Data as of March 31, 2026
1-year trailing difference

Create an account to view replication metrics

Join for free

XLVI
is actively managed and doesn’t replicate an index

Create an account to view replication quality

Join for free
PBPH
XLVI
Tracking error
Tracking difference
1 year cumulative return difference
Best
Worst
Daily return difference
Average
Worst
Advertisement
Main metrics
Last update 4/30/2026 at 1:30 PM
Live
Closed
PBPH
XLVI
Last price
$25.03
$24.97
1D performance
+3.02%
+2.11%
AuM$725.81 M$12.93 M
E/R0.13%0.35%
Characteristics
PBPH
XLVI
Management strategyPassiveActive
ProviderTidalState Street Investment Management
BenchmarkBITA Global Pharma and Biotech Select Index-
N° of holdings4956
Asset class--
Trailing 12m distribution yield
Join
Join
Inception dateNovember 24, 2025July 30, 2025
ESGNoNo
Advertisement
Exposure

Countries

PBPH
USA
63.05%
Switzerland
10.48%
Other
26.47%
XLVI
USA
96.44%
Other
3.56%

Sectors

PBPH
Health Care
85.65%
Other
14.35%
XLVI
Health Care
97.46%
Other
2.54%
Advertisement

Diversification

PBPH

Total weight of top 15 holdings out of 15

71.34%
XLVI

Total weight of top 15 holdings out of 15

70.36%

Top 15 holdings

Data as of March 31, 2026
PBPH
LILLY
12.31%
JOHNSON&JOHNSON
9.59%
ABBVIE
6.19%
MERCK & CO INC
4.79%
NOVARTIS
4.64%
CH1499059983
4.47%
GILEAD SCIENCES
4.42%
AMGEN-T
4.38%
PFIZER
4.13%
BRISTOL-MYERS SQUIBB
3.18%
DK0062498333
2.96%
VERTEX PHARMACEUTICALS
2.94%
SANOFI SA
2.68%
GSK PLC
2.67%
REGENERON PHARMACEUTICALS
2.00%
XLVI
LILLY
13.62%
JOHNSON&JOHNSON
11.01%
ABBVIE
7.19%
MERCK & CO INC
5.58%
UNITEDHEALTH GRP
4.58%
AMGEN-T
3.54%
THERMO FISHER SCIENTIFIC
3.45%
ABBOTT LABS
3.34%
GILEAD SCIENCES
3.23%
INTUITIVE SURGICAL
3.06%
PFIZER
2.98%
BRISTOL-MYERS SQUIBB
2.31%
DANAHER
2.23%
VERTEX PHARMACEUTICALS
2.12%
STRYKER
2.12%
Frequently asked questions about PBPH and XLVI

How have the PBPH and XLVI ETFs performed in 2026?

As of April 28, 2026, PBPH is down -2.73% year-to-date (YTD), while XLVI has lost -4.44%. That puts PBPH better performer ahead so far this year.

Which ETF is attracting more investor money: PBPH or XLVI?

Year-to-date, the PBPH ETF saw +$787M in flows, compared to +$2M for XLVI.

Which ETF is bigger: PBPH or XLVI?

As of April 28, 2026, PBPH holds $725.81 M in assets under management (AUM), while XLVI manages $12.93 M.

What sectors do the PBPH and XLVI ETFs invest in?

PBPH leans toward sectors like Health Care. Meanwhile, XLVI focuses on Health Care.

What are the top holdings of the PBPH ETF and XLVI ETF?

PBPH top holdings include LILLY, JOHNSON&JOHNSON and ABBVIE. XLVI holds in its top three: LILLY, JOHNSON&JOHNSON and ABBVIE.

Which ETF is more diversified: PBPH or XLVI?

PBPH holds 52 securities with 71.34% of its assets in the top 15. XLVI has 59 securities and a top 15 weight of 70.36%.

Advertisement
Advertisement
Advertisement
Webcast on Demand

Calamos Investments Powers the Next Phase of the Autocallable Revolution

Join J.P. Morgan’s Bram Kaplan, Head of Americas Equity Derivatives Strategy and Matt Kaufman from Calamos Investments as they dive into the growing global opportunity in autocallable income—an increasingly dominant strategy within structured products, now available through ETFs.

Accepted for 1 CE Credit

Calamos Webcast